February 6, 2019

PET Imaging in Potentially Evolving Treatment Paradigms in Alzheimer’s Disease

Virtual 2021 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting

Visualizing Alzheimer’s Pathology: Developments in Amyloid and Tau PET Imaging

Tammie Benzinger, MD, PhD, introduces the use of FDG, amyloid, and tau PET imaging in AD. She then explores considerations for amyloid PET, including image quantification and the recommendations and guidelines for appropriate use. Dr. Benzinger moves on to highlight the importance of amyloid PET for differential diagnosis before briefly discussing the concordance between PET imaging and cerebrospinal fluid measures of AD pathology. She closes the section by discussing the emerging role of tau PET in clinical practice.

Key Learning Objectives from Biogen’s SNMMI 2021 Symposium:

  • Provide an understanding of AD by examining its pathophysiology, epidemiology, and the treatment landscape
  • Outline the utility of PET imaging for early diagnosis of AD in the context of emerging anti-amyloid therapies
  • Explore PET findings from recent phase 3 clinical trials and through case study discussion, highlight the importance of PET imaging, and identify best practices for neurologists and radiologists to use PET for the diagnosis of AD

Disclosure: All panelists received honoraria from Biogen for participation in this symposium.

Disclaimer: All of the information discussed today is for informational purposes only; does not constitute medical advice; and is not intended to be a substitute for independent professional medical judgment, advice, diagnosis, or treatment.